Levitra Super Active
By W. Anktos. Bethel College, Newton, Kansas.
A weight loss of 10% to 15% is typical for those who diligently adhere to medication and lifestyle regimen buy 20 mg levitra super active overnight delivery, whereas a loss greater than 15% is exceptional discount levitra super active online mastercard. Treatment Modalities Weight loss can be accomplished with five treatment modalities: caloric restriction purchase levitra super active on line, physical activity, behavioral therapy, drug therapy, and surgery. For any individual, the treatment mode is determined by the degree of obesity and personal preference. As noted, the only way to lose weight is to take in fewer calories than are burned. Depending on the individual, the caloric deficit should range from 300 to 1000 kcal/day. Because fats contain more calories than either carbohydrates or proteins (on an ounce-for- ounce basis), reducing dietary fat is the easiest way to reduce calorie intake. To succeed at losing weight, it helps to know just how many calories are taken in each day and how many you burn. The following websites, which are free, have databases on foods and physical activities, along with tools to calculate and log calories taken in and calories burned: • Choose My Plate: www. Exercise makes a modest contribution to weight loss by increasing energy expenditure. In addition, exercise can help reduce abdominal fat, increase cardiorespiratory fitness, and maintain weight once loss has occurred. According to the American College of Sports Medicine, people trying to lose weight should exercise at least 150 minutes per week (and preferably more), and those trying to maintain weight loss should exercise 200 to 300 minutes per week. Behavior Modification Behavioral therapy is directed at modifying eating and exercise habits. Techniques of behavioral therapy include self-monitoring of eating and exercise habits, stress management (because stress can trigger eating), and stimulus control (limiting exposure to stimuli that promote eating). Drug Therapy In theory, drugs can promote weight loss in three ways: they can suppress appetite, reduce absorption of nutrients, or increase metabolic rate. Drugs can be used as an adjunct to diet and exercise—but only for people at increased health risk, and only after a 6-month program of diet and exercise has failed. Drugs should never be used alone; rather, they should be part of a comprehensive weight-reduction program—one that includes exercise, behavior modification, and a reduced-calorie diet. The American College of Obstetricians and Gynecologists recommends weight gain, not loss, for obese women who are pregnant, although the total amount of gain is less than that of women who are within normal limits for weight. Today, long-term treatment is recommended more often than in the past because we now know that, when drugs are discontinued, most patients regain lost weight. Accordingly, when treatment has been effective and well tolerated, it may need to continue indefinitely. Patients should lose at least 4 pounds during the first 4 weeks of drug treatment. For patients who do respond, ongoing assessment must show that (1) the drug is effective at maintaining weight loss and (2) serious adverse effects are absent. Bariatric Surgery Surgical procedures can produce significant weight loss by reducing food intake. The two most widely used procedures are gastric bypass surgery (Roux-en-Y procedure) and laparoscopic implantation of an adjustable gastric band, which reduces the effective volume of the upper part of the stomach. Surgery is effective: in 6 months to a year, patients can lose between 110 and 220 pounds. Unfortunately, the surgery can carry significant risk: in one study, mortality rates at 30 days, 90 days, and 1 year after gastric surgery were 2%, 2. Weight-Loss Drugs As previously mentioned, weight loss drugs vary in their ability to promote weight loss. The combination drug topiramate/phentermine is associated with the greatest amount of weight loss (greater than 5% of body weight). This is followed by phentermine as monotherapy and another combination drug naltrexone/bupropion, which generally achieve a weight loss of greater than 3% to 5%. Fat-soluble vitamins (A, D, E, K) should be taken at least 2 hours before or after orlistat. Naltrexone/bupropion 12-hour extended-release tablet Week 1: one tablet in the Substantial (Contrave) containing naltrexone morning increases in 8 mg/bupropion 90 mg Week 2: one tablet in the bupropion and morning; one tablet in naltrexone the evening occur when Week 3: two tablets in the taken with morning; one tablet in high-fat meals, the evening so this should Week 4 and thereafter: two be avoided. Lipase Inhibitor: Orlistat Actions and Use Orlistat [Alli, Xenical] is a novel drug approved for promoting and maintaining weight loss in obese patients 12 years and older. Specifically, the drug acts in the stomach and small intestine to cause irreversible inhibition of gastric and pancreatic lipases, enzymes that break down triglycerides into monoglycerides and free fatty acids. Patients must adopt a reduced-calorie diet in which 30% of calories come from fat. Patients treated for 2 years lost an average of 19 pounds, compared with 12 pounds for those taking placebo. Adverse Effects Gastrointestinal Effects Orlistat undergoes less than 1% absorption, and hence systemic effects are absent. Approximately 20% to 30% of patients experience oily rectal leakage, flatulence with discharge, fecal urgency, and fatty or oily stools. All of these are the result of reduced fat absorption, and all can be minimized by reducing fat intake. Possible Liver Damage Orlistat has been associated with rare cases of severe liver damage. Signs and symptoms include itching, vomiting, jaundice, anorexia, fatigue, dark urine, and light-colored stools. Other Adverse Effects Rarely, orlistat has been associated with acute pancreatitis and kidney stones, although a causal relationship has not been established. Contraindications Orlistat is contraindicated for patients with malabsorption syndrome or cholestasis. Drug and Nutrient Interactions Reduced Absorption of Vitamins By reducing fat absorption, orlistat can reduce absorption of fat-soluble vitamins (vitamins A, D, E, and K). Administration should be done 2 hours before or 2 hours after taking orlistat Drug Interactions Orlistat may cause hypothyroidism in patients taking levothyroxine by decreasing the absorption of thyroid hormone. To minimize this effect, levothyroxine and orlistat should be administered at least 4 hours apart. It suppresses appetite and creates a sense of satiety by activating hypothalamic and mesolimbic pathways that control appetite. Adverse Effects Ten percent or more of patients will experience headaches, back pain, a decrease in lymphocytes, and upper respiratory infections. About 30% of patients with diabetes will experience an increase in hypoglycemic episodes. Less common but serious adverse effects include blood dyscrasias, cognitive impairment, psychiatric disorders, priapism (prolonged penile erection), pulmonary hypertension, and valvular heart disease. Accordingly, this drug should not be given to patients at risk for these conditions. Contraindications There are life span−associated contraindications with this drug.
Broad-spectrum antibiotic and antifungal agents are being administered as source control adjuncts order levitra super active 40mg mastercard. There are a number of monitoring parameters available to help provide the best supportive care to maintain optimal end-organ perfusion order genuine levitra super active. The Su r vivin g Sepsis C a mpa ign has introduced a number of st rat egies regarding monit oring purchase on line levitra super active, resuscit at ion, and overall management of pat ient s wit h sepsis and sept ic shock. This campaign h as also out lined st rat egies for int roducing medicat ions for support of septic shock patients (norepinephrine and vasopressin), and when adjunct s such as cort icost eroids should be considered in t he care of t hese pat ient s. Sh ock can be caused by insufficient intravascular volume such as during hemorrhagic shock or hypovolemic shock due to excess fluid loss or insufficient fluid intake. Shock can also be due t o inappropriat e dist ribut ion of circulat ory volume, such as wit h neuro- genic shock (loss of regulation in vascular tone) or with septic shock (vasodilation due to circulating endogenous vasodilators). T his imaging modalit y can be quit e useful for the evaluation of critically ill, hemodynamically unstable patients. S er u m lact at e can also become elevat ed as t he result of inadequat e clearance, such as wit h renal dysfunction. T hese pressure measurements can help gauge the patients’ left ventricular functions. The cardiovascular system can be considered as an arrangement of pump, pipes, and fluid volume. This sim p list ic id ea t ranslates to t he t hree primary component s of cardiovascular physiology: namely, car diac out put ( pu mp), vascu lar t on e ( pip es), an d int r avascu lar volu me (flu id). All comp on ent s of the syst em n eed t o be int act t o maint ain n or mal p er fu sion. D ys- fu n ct ion in on e or m or e of t h ese comp on en t s will oft en con t r ibut e t o h yp ot en sion and shock. Evaluat ion of a pat ient wit h postoperat ive hypotension should include a review of t he pert inent hist ory including medicat ions, a careful physical exami- nation, the trend in vital signs and urine output. Table 3– 1 lists the differential diagnoses of common causes of hypotension in the perioperative period, and Table 3– 2 shows t he hemodynamic charact eristcs. Dia g n o sis The keys to assessment and management of hypotensive patients include close monitoring of the vital signs, urine output, and clinical appearances. It is important to note the changes in these parameters over time and after interventions. A Foley cat h et er for cont inu ou s u r in e out put m on it or in g, ser ial ar t er ial blood gas m easu r e- ments for trends in base deficit and lactate levels, and arterial catheterization for cont in u ou s blood pr essu r e m easu r em en t s can b e h elpfu l. Sim ilar ly, ser ial h em oglo- bin measurements can be helpful to identify ongoing occult bleeding. Hyp o vo le m ia Hypovolemic surgical patients who respond initially to crystalloid resuscitation but then experience subsequent drops in blood pressure may have ongoing bleeding that require operative intervention to control hemorrhage. It is very critical to remem- ber that ongoing blood loss may be the cause for hypovolemia in surgical patients. Accordingly, the t reat ment is source cont rol and not cont inued resuscit at ion. Also, in t h ese sett ings, resuscit at ions are generally more effect ive wit h t he administ ra- tion of blood products rather than crystalloids. Excess crystalloid administration to a bleeding patient can cause dilution of clotting factors and thrombocytopenia, which can cause further bleeding and create a vicio us cycle of worsening hypo ten- sion, coagulopathy, and hypothermia. Dist rib u t ive Sh o ck Hypovolemia can also be caused by changes in patients’a patient’s vascular tone such as in t he set t ing of neurogenic shock and inappropriat e vasodilat ory response from sep t ic sh ock or an aph ylaxis. In con t r ast t o the bleed in g patient, most patient s wit h dist ribut ive shock exhibit gradual dips in blood pressure or minimal responses to fluid administration. It is important to recognize these conditions, since the appropriate treat- ments are administration of vasoconstrictive medications such as norepinephrine for septic shock or phenylephrine (apha-1 agonist) for neurogenic shock rather than con- tinued fluid administration. Se p s is Sepsis refers t o t he hyperdynamic and febrile responses t o infect ions. Severe sepsis is defined as the occurrence of infect ion with septic host response and at least one end-organ dysfunct ion. Septic shock is defined as sepsis with persistent hypotension despite fluid administration. Early Goal-D irected Therapy is a treatment approach for sepsis that was int rodu ced during the early 2000s; this approach is direct ed at early recognit ion of sepsis and early aggressive t reat ment t o rest ore or minimize tissue hypoperfusion. It is important to recognize that severe sepsis can carry a mortality of 25% to 30% and septic shock can carry a mortality of 50%. The two major treatment goals in septic shock are to identify and address the source of infec- tion (source control), and to restore tissue perfusion as soon as possible to minimize remote organ hypoperfusion that can lead to organ dysfunction. Time to antibiotic initiation has been well documented to influence outcomes associated with sepsis; therefore, every effort should be made t o select and administ er t he appropriat e ant imicrobial treatments as soon as sepsis is recognized. The Su r vivin g Sepsis C a mpa ign is an international initiative to enhance the practice of sepsis management. If fluids alone are insufficient to achieve the blood pres- sure goals, a norepineph rine (Levophed) drip is recommended t o help ach ieve the target blood pressures once intravascular volume depletion has been corrected. If cont inu ed in cr eases in n or epin eph r in e in fu sion fail t o ach ieve t ar get blood pr es- sures, a cont inuous infusion of vasopressin at a const ant rat e of 0. The use of physi- ologic doses of corticosteroids can be considered for individuals with septic shock wh o do not ach ieve sufficient responses t o source cont rol, fluid administ rat ion, and vaso p r esso r s. Ca r d i o g e n i c Sh o c k : In t r i n s i c o r Ex t r i n s i c ( Me c h a n i c a l ) Intrinsic conditions causing cardiogenic shock are due to primary cardiac dysfunc- tion, and these include acute coronary syndrome, acute myocardial infarction, and heart failure. Conversely, a classic extrinsic cause of cardiogenic shock is ten- sion pneumot horax where t he mediast inal st ruct ures shift away from t he side of the pneumothorax causing kinking of the vena cava and affecting cardiac filling. Another example of an ext rinsic cause of cardiogenic shock is cardiac t amponade, in wh ich pericardial pressure compromises venous return t o t he right heart and hypotension. Ch est auscult at ion, chest x-rays, and echocardiography are maneuvers and modalities that can be helpful to identify patients with extrinsic causes of cardiac dysfunction. Mixe d Ca u s e s o f Sh o c k In some cases, hypotension and hemodynamic instability can be attributable to more than one cause. For example, an elderly man with a history of congestive heart failure wit h urinary t ract sepsis can h ave hypot ension due t o the combined effect s of cardiogenic and septic causes. For such an individual, echocardiography can be highly useful to determine cardiac function as well as intravascular volume status. The treatment of such a patient often requires prioritizing the more serious condi- tion or sometimes requires simultaneous treatment of both conditions. H is heart rate is 112 beats/ minute, respiratory rate is 24 breath/ minute, and temperature is 37. I n t r aven o u s fu r o sem id e ( Lasix) sh o u ld b e ad m in ist er ed t o im p r o ve h is urine output C. This patient likely is affected by anxiety and a mild anxiolytic should be provided with close observation D. T h e pat ient is not ed t o have low urine out put, wit h only 20 mL collected over 3 hours. H er blood pressure is 90/ 55 mm H g, heart rate is 110 beats/ minute, and temperature is 35.
In response to arteriolar dilation purchase 40mg levitra super active fast delivery, peripheral resistance and arterial blood pressure fall best order for levitra super active. In addition order levitra super active master card, heart rate and myocardial contractility increase, largely by reflex mechanisms. Because hydralazine acts selectively on arterioles, postural hypotension is minimal. Pharmacokinetics Absorption and Time Course of Action Hydralazine is readily absorbed after oral administration. With parenteral administration, effects begin faster (within 10 minutes) and last 2 to 4 hours. Metabolism Hydralazine is inactivated by a metabolic process known as acetylation. The distinction between rapid and slow acetylators can be clinically significant because individuals who acetylate hydralazine slowly are likely to have higher blood levels of the drug, which can result in excessive vasodilation and other undesired effects. Therapeutic Uses Essential Hypertension Oral hydralazine can be used to lower blood pressure in patients with essential hypertension. The regimen almost always includes a beta blocker and may include a diuretic as well (Table 38. Although commonly employed in the past, hydralazine has been largely replaced by newer antihypertensive agents (see Chapter 39). Heart Failure As discussed in Chapter 40, hydralazine (usually in combination with isosorbide dinitrate) can be used short term to reduce afterload in patients with heart failure. Adverse Effects Reflex Tachycardia By lowering arterial blood pressure, hydralazine can trigger reflex stimulation of the heart, thereby causing cardiac work and myocardial oxygen demand to increase. Because hydralazine-induced reflex tachycardia is frequently severe, the drug is usually combined with a beta blocker. Increased Blood Volume Hydralazine-induced hypotension can cause sodium and water retention and a corresponding increase in blood volume. Symptoms include muscle pain, joint pain, fever, nephritis, pericarditis, and the presence of antinuclear antibodies. The syndrome occurs most frequently in slow acetylators and is rare when dosage is kept below 200 mg/day. Other Adverse Effects Common responses include headache, dizziness, weakness, and fatigue. Drug Interactions Hydralazine can be combined with a beta blocker to protect against reflex tachycardia and with a diuretic to prevent sodium and water retention and expansion of blood volume. Drugs that lower blood pressure will intensify hypotensive responses to hydralazine. Accordingly, if hydralazine is used with other antihypertensive agents, care is needed to avoid excessive hypotension. In the treatment of heart failure, hydralazine is usually combined with isosorbide dinitrate, a drug that dilates veins. Minoxidil Minoxidil produces more intense vasodilation than hydralazine but also causes more severe adverse reactions. Because it is both very effective and very dangerous, minoxidil is reserved for patients with severe hypertension unresponsive to safer drugs. Cardiovascular Effects Like hydralazine, minoxidil produces selective dilation of arterioles. Both responses can increase cardiac oxygen demand and can thereby exacerbate angina pectoris. Pharmacokinetics Minoxidil is rapidly and completely absorbed after oral administration. Therapeutic Uses The only cardiovascular indication for minoxidil is severe hypertension. Because of its serious adverse effects, minoxidil is reserved for patients who have not responded to safer drugs. To minimize adverse responses (reflex tachycardia, expansion of blood volume, pericardial effusion), minoxidil should be used with a beta blocker plus intensive diuretic therapy. Topical minoxidil [Rogaine, others] is used to promote hair growth in balding men and women (see Chapter 85). Adverse Effects Reflex Tachycardia Blood pressure reduction triggers reflex tachycardia, a serious effect that can be minimized by cotreatment with a beta blocker. If diuretics are inadequate, dialysis must be employed, or minoxidil must be withdrawn. Hypertrichosis About 80% of patients taking minoxidil for 4 weeks or more develop hypertrichosis (excessive growth of hair). Hypertrichosis appears to result from proliferation of epithelial cells at the base of the hair follicle; vasodilation may also be involved. Hairiness is a cosmetic problem that can be controlled by shaving or using a depilatory. However, many patients find hypertrichosis both unmanageable and intolerable and refuse to continue treatment. B l a c k B o x Wa r n i n g : M i n o x i d i l Minoxidil can cause pericardial effusion, occasionally progressing to tamponade, and may exacerbate angina pectoris. Other Adverse Effects Minoxidil may cause nausea, headache, fatigue, breast tenderness, glucose intolerance, thrombocytopenia, and skin reactions (rashes, Stevens-Johnson syndrome). In addition, the drug has caused hemorrhagic cardiac lesions in experimental animals. Patient-Centered Care Across the Life Span Vasodilators Life Stage Patient Care Concerns Infants Hydralazine is used in infants as young as 1 month for management of chronic hypertension. Children/adolescents Hydralazine can be used safely in children, just in smaller doses. Breastfeeding Data are lacking regarding transmission of drug from mother to infant via breast milk. According to the World Health Organization, hypertension is the leading global risk for mortality, causing 12. Left untreated, hypertension can lead to heart disease, kidney disease, and stroke. As a result, treatment must continue lifelong, making nonadherence a significant problem. In 2014, the Journal of the American Medical Association issued revised clinical guidelines on hypertension. Throughout this chapter, clinical practice recommendations reflect those in the 2014 hypertension 1 guidelines, except where noted otherwise. This scheme differs significantly from the 2014 hypertension guidelines, which no longer separate hypertension into different categories. Types of Hypertension There are two broad categories of hypertension: primary hypertension and secondary hypertension.